The incidence was numerically lower in patients with non-breast cancer versus breast cancer (11.4% versus 18.1%) and in patients with HER2-positive breast cancer who were treated with a lower dose (5.4 mg/kg, 13.7%; 6.4 mg/kg, 22.8%). This evidence concerns the gene ERBB2 and breast carcinoma.